Exploratory Economic Evaluation of a Genome Precision Report in Kidney and Liver Transplantation Care
Value in Health · 2026-11 · 29 (11) · 1996-2007
DOI: 10.1016/j.jval.2026.06.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-11. Verfasst von Florencia Sjaaf und 10 weiteren Autor:innen. Beteiligte Einrichtung: Economics of Genomics and Precision Medicine Unit, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Aus…. Hauptthemen laut MEDLINE: Liver Transplantation, Kidney Transplantation, Precision Medicine. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Government of Victoria.
Abstract (Originalsprache)
OBJECTIVES: To investigate the impact of including 4 domains of kidney and liver transplantation care (tacrolimus optimization, postoperative complications prevention, screening, and familial testing) on the cost-effectiveness of a genome precision report and identify key parameters driving the cost-effectiveness. METHODS: A decision tree model-based cost-utility analysis comparing a genome precision report with standard nongenomic practice from the Australian healthcare system perspective was conducted, using data from the literature (lifetime costs and quality-adjusted life-years [QALYs] discounted at 3% to 5%, following the source studies) and the Clinical Change Project study. Costs were in 2024 Australian dollars (US dollar values converted using purchasing power parities). We conducted a stepped evaluation that sequentially added each domain, and deterministic and probabilistic sensitivity analyses. RESULTS: With only the tacrolimus optimization and the postoperative complication prevention domains included, the incremental cost and QALY compared with standard practice were AU$2030 (US$1471) and 0.0003, respectively (incremental cost-effectiveness ratio: AU$6.2 million [US$4.5 million] per QALY gained). Including all 4 domains reduced the incremental cost to AU$1800 (US$1300) and increased the QALYs gained to 0.0170 (incremental cost-effectiveness ratio: AU$106 000 [US$77 000] per QALY gained). Results were sensitive to genomic test cost, incremental cost and QALY after germline cancer and cardiovascular conditions screening, rejection rates, and cascade-testing uptake. The probability of cost-effectiveness was 0.14 to 0.79 at AU$50 000 to 150 000 (US$36 234-108 701) per QALY thresholds. CONCLUSION: Considering wider benefits of genomic medicine can materially change its estimated cost-effectiveness. Lower genomic test cost and better quantification of genotype-guided tacrolimus dosing benefits could improve its cost-effectiveness in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Economics of Genomics and Precision Medicine Unit, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia. Electronic address: f.sjaaf@unimelb.edu.au.
- Department of Genomic Medicine, The Royal Melbourne Hospital, Parkville, VIC, Australia.
- Department of Nephrology and Kidney Care Services, The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Medicine, The University of Melbourne, Parkville, VIC, Australia; The Walter and Eliza Hall Insti…
- Victorian Liver Transplant Unit, Austin Health, Heidelberg, VIC, Australia; Department of Surgery, The University of Melbourne, Parkville, VIC, Australia.
- Department of Pathology, The Royal Melbourne Hospital, Parkville, VIC, Australia.
- Economics of Genomics and Precision Medicine Unit, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia; Murdoch Children's Research Institute, Parkville, VIC, Austral…
Förderung
- State Government of Victoria
Zitieren
APA
Sjaaf, F., Pang, L., Kuo, S. F. T., Vaz, K., Thompson, B. A., Goranitis, I., Gaff, C., Martyn, M., James, P., Schilling, C., & Melbourne Genomics Health Alliance Clinical Change Project (2026). Exploratory Economic Evaluation of a Genome Precision Report in Kidney and Liver Transplantation Care. Value in Health, 29(11), 1996-2007. https://doi.org/10.1016/j.jval.2026.06.013
Vancouver
Sjaaf F, Pang L, Kuo SFT, Vaz K, Thompson BA, Goranitis I, et al. Exploratory Economic Evaluation of a Genome Precision Report in Kidney and Liver Transplantation Care. Value in Health. 2026;29(11):1996-2007. doi:10.1016/j.jval.2026.06.013
BibTeX
@article{Sjaaf2026,
author = {Sjaaf, Florencia and Pang, Lokman and Kuo, Stephanie F T and Vaz, Karl and Thompson, Bryony A and Goranitis, Ilias and Gaff, Clara and Martyn, Melissa and James, Paul and Schilling, Chris and Melbourne Genomics Health Alliance Clinical Change Project, Melbourne Genomics Health Alliance Clinical Change Project},
title = {Exploratory Economic Evaluation of a Genome Precision Report in Kidney and Liver Transplantation Care},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {11},
pages = {1996--2007},
doi = {10.1016/j.jval.2026.06.013}
}
EUVIMED